Please assess the completion status of the following clinical trial:

Trial Title: PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Phase I study: patients with advanced carcinomatosis from ovarian, breast, gastric, or pancreatic origin. No alternative systemic treatment options are available.~* Age over 18 years~* Adequate performance status (Karnofsky index \> 60%)~* Absence of intestinal or urinary obstruction~* Limited size of the majority of peritoneal tumor implants (\< 5 mm)~* Absent or limited ascites~* Ability to understand the proposed treatment protocol and provide informed consent~* Expected life expectancy more than 6 months~* Laboratory data~  * Serum creatinine ≤ 1.5 mg/dl or a calculated GFR (CKD-EPI) ≥ 60 mL/min/1.73 m²~ * Serum total bilirubin ≤ 1.5 mg/dl, except for known Gilbert's disease~ * Platelet count \> 100.000/µl~ * Hemoglobin \> 9g/dl~ * Neutrophil granulocytes \> 1.500/ml~ * No major blood coagulation disorders. Parameters within normal range.~* Absence of alcohol and/or drug abuse~* No other concurrent malignant disease~* Written informed consent~Exclusion Criteria:~* Pregnancy or breast feeding. Women who can become pregnant must ensure effective contraception.~* Active bacterial, viral or fungal infection~* Active gastro-duodenal ulcer~* Parenchymal liver disease (any stage cirrhosis)~* Uncontrolled diabetes mellitus~* Psychiatric pathology affecting comprehension and judgement faculty~* General or local (abdominal) contra-indications for laparoscopic surgery~* Documented intolerance or allergy to paclitaxel~* Patients who receive other taxane therapy until three weeks before the first experimental treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abraxane 35 mg/m² (Type: EXPERIMENTAL): PIPAC with Abraxane (35 mg/m²) will be administered every 4 weeks for 3 cycles.
- Abraxane 70 mg/m² (Type: EXPERIMENTAL): PIPAC with Abraxane (70 mg/m²) will be administered every 4 weeks for 3 cycles.
- Abraxane 90 mg/m² (Type: EXPERIMENTAL): PIPAC with Abraxane (90 mg/m²) will be administered every 4 weeks for 3 cycles.
- Abraxane 112.5 mg/m² (Type: EXPERIMENTAL): PIPAC with Abraxane (112.5 mg/m²) will be administered every 4 weeks for 3 cycles.
- Abraxane 140 mg/m² (Type: EXPERIMENTAL): PIPAC with Abraxane (140 mg/m²) will be administered every 4 weeks for 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).